Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
As a company patent portfolio, Sirius Therapeutics Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, BRETZ, COREY LANE, who is the busiest examiner for the portfolio with 1 pending office action. The prosecution is situated within 1 distinct art unit, reflecting a focused area of technical inquiry for the company.
The presence of 1 pending office action means that the company's current interaction with the USPTO is limited to a single case. Because there is only 1 distinct examiner and 1 distinct art unit involved, the prosecution strategy is straightforward and lacks the variability of larger portfolios. Practitioners can concentrate on the specific requirements of BRETZ, COREY LANE to resolve the 1 pending office action. This localized activity allows for a dedicated focus on the examination nuances of the art unit involved, which can lead to more predictable prosecution timelines for the applicant.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRETZ, COREY LANE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18603124 | POLYNUCLEOTIDE CONSTRUCTS | BRETZ, COREY LANE | — |
| Art Unit | Apps |
|---|---|
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18603124 | POLYNUCLEOTIDE CONSTRUCTS | BRETZ, COREY LANE | 1600 | §103DP | Non-Final OA | — | Pending | Mar 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial